|Budget Amount *help
¥42,770,000 (Direct Cost: ¥32,900,000、Indirect Cost: ¥9,870,000)
Fiscal Year 2015: ¥10,010,000 (Direct Cost: ¥7,700,000、Indirect Cost: ¥2,310,000)
Fiscal Year 2014: ¥10,010,000 (Direct Cost: ¥7,700,000、Indirect Cost: ¥2,310,000)
Fiscal Year 2013: ¥9,880,000 (Direct Cost: ¥7,600,000、Indirect Cost: ¥2,280,000)
Fiscal Year 2012: ¥12,870,000 (Direct Cost: ¥9,900,000、Indirect Cost: ¥2,970,000)
|Outline of Final Research Achievements
In order to improve the world leading heavy ion radiotherapy, we studied the combination regimen of Hsp90 inhibitor and carbon-ion irradiation. After screening and studying various inhibitors, we found that most Hsp90 inhibitors can cause tumor specific radio-sensitization with heavy ions and the cause of this was shown to be inhibition of DNA double strand break (DSB) repair by the inhibitors. Among these we suggest that an Hsp90 inhibitor TAS-116 might be most recommendable clinically due to its low toxicity.
We also studied the combination effects of a DNA DSB repair inhibitor NU7441 and radiation including heavy ions. Our investigation indicated that a non-toxic concentration of NU7441 radio-sensitized tumor cells and the cause seems to be related to disturbed cell cycle progression. Moreover, some tumor cells show senescence like appearance after the combination treatment. Our study forms a biological basis for a new combination cancer therapy including particle radiation.